Health technology assessment of pathogen reduction technologies applied to plasma for clinical use

Blood Transfusion

Volumn 14, Issue 4, 2016, Pages 287-386

  Cicchetti, Americo ^a   Berrino, Alexandra ^b   Casini, Marina ^a   Codella, Paola ^a   Facco, Giuseppina ^c   Fiore, Alessandra ^a   Marano, Giuseppe ^c   Marchetti, Marco ^b   Midolo, Emanuela ^a   Minacori, Roberta ^a   Refolo, Pietro ^a   Romano, Federica ^a   Ruggeri, Matteo ^a   Sacchini, Dario ^a   Spagnolo, Antonio G ^a   Urbina, Irene ^b   Vaglio, Stefania ^c   Grazzini, Giuliano ^c   Liumbruno, Giancarlo M ^c  

^a CATHOLIC UNIVERSITY   (Italy)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Fresh frozen plasma; Health technology assessment; Pathogen inactivation; Pathogen reduction; Transfusion safety

Indexed keywords

AMOTOSALEN; DETERGENT; FIBRINOGEN; FRESH FROZEN PLASMA; IODINE; METHYLENE BLUE; OCTAPLAS; PROTEIN S; RIBOFLAVIN; SOLVENT; THROMBOPLASTIN; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

AUSTRALIA AND NEW ZEALAND; AUSTRIA; BELGIUM; BENEFICENCE; BLOOD DONOR; BLOOD SAFETY; BLOOD SAMPLING; BLOOD STORAGE; BLOOD TRANSFUSION REACTION; CANADA; CHROMATOGRAPHY; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; CRYOPRECIPITATE; DONOR SELECTION; ECONOMIC EVALUATION; FINLAND; FRACTIONATION; FRANCE; FREEZE DRYING; GERMANY; GREECE; HEALTH CARE SYSTEM; HEALTH EQUITY; HEAT TREATMENT; HUMAN; INFORMED CONSENT; IRELAND; ITALY; JUSTICE; LIFE CYCLE; LYOPHILISATE; MEDICAL ETHICS; MEDICAL INFORMATION; NANOFILTRATION; NORWAY; PARTIAL THROMBOPLASTIN TIME; PASTEURIZATION; PATHOGEN CLEARANCE; PHOTOTHERAPY; PLASMA TRANSFUSION; PRACTICE GUIDELINE; PROTHROMBIN TIME; QUALITY CONTROL; REVIEW; SPAIN; SWITZERLAND; TRANSFUSION ASSOCIATED GRAFT VERSUS HOST DISEASE; TRANSFUSION RELATED ACUTE LUNG INJURY; TREATMENT INDICATION; ULTRAVIOLET RADIATION; UNITED KINGDOM; UNITED STATES; VASCULARIZATION; VIRUS INACTIVATION; ADVERSE EFFECTS; ANIMAL; BACTERIUM; BLOOD TRANSFUSION; DISINFECTION; ISOLATION AND PURIFICATION; MICROBIOLOGY; PLASMA; PROCEDURES; VIROLOGY; VIRUS;

ANIMALS; BACTERIA; BLOOD SAFETY; BLOOD TRANSFUSION; DISINFECTION; HUMANS; PLASMA; VIRUSES;

EID: 84992017501     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2016.0065-16     Document Type: Review

References (349)

1. Psychogios N, Hau DD, Peng J, et al. The human serum metabolome. PLoS One 2011;16:e16957.
2. Benjamin RJ, McLaughlin LS. Plasma components: properties, differences, and uses. Transfusion 2012;52:9S-19S.
3. Sherwood L. Human Physiology: From Cells to Systems. 8th ed. Belmont, CA: Brooks/Cole-Cengage Learning; 2013.
4. Strumia MM, McGraw JJ. The development of plasma preparations for transfusions. Ann Intern Med 1941;15:80-8.
5. Gosselin RC, Marshall C, Dwyre DM, et al. Coagulation profile of liquid-state plasma. Transfusion 2013;53:579-90.
6. Grazzini G, Mannucci PM, Oleari F. Plasma-derived medicinal products: demand and clinical use. Blood Transfus 2013;11:s2-5.
7. Burnouf T. Plasma fractionation. ISBT Science Series 2012;7:62-7.
8. Labarinas S, Arni D, Karam O. Plasma in the PICU: why and when should we transfuse? Ann Intensive Care 2013;3:16.
9. Alhumaidan H, Cheves T, Holme S, Sweeney J. Stability of coagulation factors in plasma prepared after a 24-hour room temperature hold. Transfusion 2010;50:1934-42.
10. Council of Europe. Guide to the Preparation, Use and Quality Assurance of Blood Components. Recommendation No R (95) 15 on the Preparation, Use and Quality Assurance of Blood Components. 17th ed. Strasbourg: Council of Europe Press; 2013.
11. Yang L, Stanworth S, Baglin T. Cryoprecipitate: an outmoded treatment? Transfus Med 2012;22:315-20.
12. Kappler S, Ronan-Bentle S, Graham A. Thrombotic microangiopathies (TTP, HUS, HELLP). Emerg Med Clin North Am 2014;32:649-71.
13. O'Shaughnessy DF, Atterbury C, Bolton Maggs P, et al.; British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004;126:11-28.
14. Liumbruno G, Bennardello F, Lattanzio A, et al; Italian Society of Transfusion Medicine and Immunohaematology (SIMTI) Work Group. Recommendations for the transfusion of plasma and platelets. Blood Transfus 2009;7:132-50.
15. Italian National Institute of Health. Giampaolo A, Barca A, Catalano L, Hassan HJ. Proceedings of national meeting on appropriate use of blood, Rome, February 25-26, 2003. In: Rapporti ISTISAN 04/10. Italian National Institute of Health 2004; ix: 1-186.
16. Seghatchian J, de Sousa G. Pathogen-reduction systems for blood components: the current position and future trends. Transfus Apher Sci 2006;35:189-96.
17. Moor AC, Dubbelman TM, VanSteveninck J, Brand A. Transfusion-transmitted diseases: risks, prevention and perspectives. Eur J Haematol 1999;62:1-18.
18. Bihl F, Castelli D, Marincola F, et al. Transfusion-transmitted infections. J Transl Med 2007;5:25.
19. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996;334:1685-90.
20. AuBuchon JP, Dodd RY. Inactivation of microbial contaminants of blood components. Clin Lab Med 1992;12:787-803.
21. Molaro GL. La prevenzione del rischio trasfusionale infettivo e immunologico con il plasma fresco congelato trattato con il metodo del solvente/detergente. Blood Transf 2001;46:1-9.
22. Friedman C, Newsom W. IFIC Basic Concepts of Infection Control. 2nd ed. - Revised 2011. International Federation of Infection Control; 2011.
23. World Health Organization. Screening Donated Bloods for Transfusion-Transmissible-Infections. Available at: http://www.who.int/bloodsafety/ScreeningTTI.pdf. Accessed on 10/12/2014.
24. Leparc GF. Nucleic acid testing for screening donor blood. Infect Med 2000;17.
25. Jongerius JM, Wester M, Cuypers HT, et al. New hepatitis B virus mutant form in a blood donor that is undetectable in several hepatitis B surface antigen screening assays. Transfusion 1998;38:56-9.
26. Jerome KR. Lennette's Laboratory Diagnosis of Viral Infections. 4th ed. New York: Informa Healthcare USA, Inc; 2010.
27. Bianco C. Choice of human plasma preparations for transfusion. Transfus Med Rev 1999;13:84-8.
28. del Río-Garma J, Alvarez-Larrán A, Martínez C, et al. Methylene blue-photoinactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study. Br J Haematol 2008;143:39-45.
29. Molaro GL. [Universal leucodepletion. Part one]. Il Servizio Trasfusionale 2000;29. [In Italian.]
30. Dodd RY, Notari EP 4th, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002;42:975-9.
31. Dodd RY, Leiby DA. Emerging infectious threats to the blood supply. Annu Rev Med 2004;55:191-207.
32. Mohr H, Knüver-Hopf J, Gravemann U, et al. West Nile virus in plasma is highly sensitive to methylene blue-light treatment. Transfusion 2004;44:886-90.
33. Leydold SM, Farcet MR, Kindermann J, et al. Chikungunya virus and the safety of plasma products. Transfusion 2012;52:2122-30.
34. Vanlandingham DL, Keil SD, Horne KM, et al. Photochemical inactivation of chikungunya virus in plasma and platelets using the Mirasol pathogen reduction technology system. Transfusion 2013;53:284-90.
35. Rock G. A comparison of methods of pathogen inactivation of FFP. Vox Sang 2011;100:169-78.
36. Mundt JM, Rouse L, Van den Bossche J, Goodrich RP. Chemical and biological mechanisms of pathogen reduction technologies. Photochem Photobiol 2014;90:957-64.
37. Horowitz B, Bonomo R, Prince AM, et al. Solvent/detergenttreated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood 1992;79:826-31.
38. Garwood M, Cardigan RA, Drummond O, et al. The effect of methylene blue photoinactivation and methylene blue removal on the quality of fresh-frozen plasma. Transfusion 2003;43:1238-47.
39. Naegelen C, Isola H, Dernis D, et al. Evolution of techniques for preparation of labile blood products (LBP): pathogen inactivation in LBP. Transfus Clin Biol 2009;16:179-89.
40. Webert KE, Cserti CM, Hannon J, et al. Proceedings of a Consensus Conference: pathogen inactivation - making decisions about new technologies. Transfus Med Rev 2008;22:1-34.
41. Horowitz B, Lazo A, Grossberg H, et al. Virus inactivation by solvent/detergent treatment and the manufacture of SD plasma. Vox Sang 1998;74:203-6.
42. Seltsam A, Müller TH. UVC irradiation for pathogen reduction of platelet concentrates and plasma. Transfus Med Hemother 2011;38:43-54.
43. Klein HG, Anderson D, Bernardi MJ, et al. Pathogen inactivation: making decisions about new technologies. Report of a consensus conference. Transfusion 2007;47:2338-47.
44. European Directorate for the Quality of Medicines & HealthCare. Symposium on Implementation of Pathogen Reduction Technologies for Blood Components. Executive Summary. Strasbourg, France; 2010.
45. Osselaer JC, Debry C, Goffaux M, et al. Coagulation function in fresh-frozen plasma prepared with two photochemical treatment methods: methylene blue and amotosalen. Transfusion 2008;48:108-17.
46. French Ministry of Health. [Decision of 20 October 2010 establishing the list and the characteristics of blood components.] JORF 28 November 2010. [In French.]
47. Agence Française de Sécurité Sanitaire des produits de Santé (AFSSAPS). Haemovigilance Annual report 2010. Available at: http://ansm.sante.fr/var/ansm-site/storage/original/application/365a9 7e590280fb1192c05a838cb97bb.pdf. Accessed on 02/12/2014.
48. Mertes PM, Demoly P, Alperovitch A, et al. Methylene bluetreated plasma: an increased allergy risk? J Allergy Clin Immunol 2012;130:808-12.
49. Seltsam A, Mueller TH. Updated hemovigilance data do not show an increased risk of allergic reactions to methylene blue-treated plasma. J Allergy Clin Immunol 2013;131:1253-4.
50. Ozier Y, Muller JY, Mertes PM, et al. Transfusion-related acute lung injury: reports to the French Hemovigilance Network 2007 through 2008. Transfusion 2011;51:2102-10.
51. Lambrecht B, Mohr H, Knüver-Hopf J, Schmitt H. Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light. Vox Sang 1991;60:207-13.
52. Seghatchian J, Struff WG, Reichenberg S. Main properties of the THERAFLEX MB plasma system for pathogen reduction. Transfus Med Hemother 2011;38:55-64.
53. Politis C, Kavallierou L, Hantziara S, et al. Quality and safety of fresh-frozen plasma inactivated and leucoreduced with the Theraflex methylene blue system including the Blueflex filter: 5 years' experience. Vox Sang 2007;92:319-26.
54. Murphy WG. Pathogen reduction: state of reflection in Ireland. Transfus Clin Biol 2011;18:488-90.
55. De Silvestro G, Bagatella P, Tison T, et al. Virus-inactivated plasma - Plasmasafe: a one-year experience. Blood Transfus 2007;5:134-42.
56. Equitani F, Mistretta G, Mele L, et al. Methylene bluephotoinactivated fresh frozen plasma is an effective and safe treatment for inherited and acquired coagulopathies and bleeding disorders. Blood 2003;102:138b.
57. ®) for the Inactivation of Pathogens for Transfusion Therapy. Catalan Agency for Health Information, Assessment and Quality. INAHTA Briefs Issue 2009/103.
58. Jimenez-Marco T, Ruiz-Alderton D, Bautista-Gili AM, Girona-Llobera E. Role of riboflavin- and UV light-treated plasma in prevention of transfusion-related acute lung injury. Transfus Med Hemother 2014;41:172-5.
59. INTERCEPT Use Overview. 2014 Cerus Corporation. Available at: http://www.interceptbloodsystem.com/interceptinuse/overview. Accessed on 10/12/2014.
60. Hellstern P, Solheim BG. The use of solvent/detergent treatment in pathogen reduction of plasma. Transfus Med Hemother 2011;38:65-70.
61. ™. Transfus Med Hemother 2011;38:19-31.
62. Adelaide Health Technology Assessment (AHTA) Technology Report, July 2011. Technologies for the inactivation/reduction of pathogens in blood products.
63. Canadian Agency for Drugs and Technologies in Health, CADHT Technology Report, March 2011. Octaplas compared with fresh frozen plasma to reduce the risk of transmitting lipid-enveloped viruses: an economic analysis and budget impact analysis.
64. FDA News Release. FDA approves Octaplas to treat patients with blood clotting disorders. January 17, 2013. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm336009.htm. Accessed on 02/12/2014.
65. FDA News Release. FDA approves first pathogen reduction system to treat plasma. December 16, 2014. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427111.htm. Accessed on 20/12/2014.
66. Solheim BG, Seghatchian J. Update on pathogen reduction technology for therapeutic plasma: an overview. Transfus Apher Sci 2006;35:83-90.
67. World Health Organization. Fact sheet No 279. Blood safety and availability. Updated June 2014. Available at: http://www.who.int/mediacentre/factsheets/fs279/en/. Accessed on 02/12/2014.
68. World Health Organization. WHO Library Cataloguing-in-Publication Data: Towards 100% voluntary blood donation: a global framework for action. Available at: www.who. int/bloodsafety/voluntary-donation/en/. Accessed on 02/12/2014.
69. Polizzotto MN, Wood EM, Ingham H, Keller AJ; Australian Red Cross Blood Service Donor and Product Safety Team. Reducing the risk of transfusion-transmissible viral infection through blood donor selection: the Australian experience 2000 through 2006. Transfusion 2008;48:55-63.
70. Special Issue: The evolving paradigm of patient blood management. Transfusion 2014;54:2587-790.
71. Clarke P, Will RG, Ghani AC. Is there the potential for an epidemic of variant Creutzfeldt-Jakob disease via blood transfusion in the UK? J R Soc Interface 2007;4:675-84.
72. European Centre for Disease Prevention and Control. Questions on variant Creutzfeldt-Jakob disease and blood transfusion; 2011. Available at: http://ecdc.europa.eu/en/publications/-layouts/forms/Publication-DispForm. aspx?ID=477&List=4f55ad51-4aed-4d32-b960-af70113dbb90. Accessed on 02/12/2014.
73. Food and Drug Administration. Guidance for Industry. Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by Blood and Blood Products. Available at: http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegula toryInformation/GuidanceSDefault.htm. Accessed on 02/12/2014.
74. Blajchman MA. The clinical benefits of the leukoreduction of blood products. J Trauma 2006;60:S83-90.
75. International Atomic Energy Agency. Effects of ionizing radiation on blood and blood components: A survey. Vienna: IAEA-TECDOC-934; 1997.
76. World Health Organization. Annex 4 Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products. WHO Technical Report, Series No. 924, 2004.
77. D'Alessandro A, Zolla L. Proteomics for quality-control processes in transfusion medicine. Anal Bioanal Chem 2010;398:111-24.
78. Fournier-Wirth C, Coste J. Fitting new technologies into the safety paradigm: use of microarrays in transfusion. Dev Biol (Basel) 2007;127:61-70.
79. Fournier-Wirth C, Jaffrezic-Renault N, Coste J. Detection of blood-transmissible agents: can screening be miniaturized? Transfusion 2010;50:2032-45.
80. Velthove KJ, Over J, Abbink K, Janssen MP. Viral safety of human plasma-derived medicinal products: impact of regulation requirements. Transfus Med Rev 2013;27:179-83.
81. Burnouf T. Modern plasma fractionation. Transfus Med Rev 2007;21:101-17.
82. Klamroth R, Gröner A, Simon TL. Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates. Transfusion 2014;54:1406-17.
83. Unger U, Poelsler G, Modrof J, Kreil TR. Virus inactivation during the freeze-drying processes as used for the manufacture of plasma-derived medicinal products. Transfusion 2009;49:1924-30.
84. Stadler M, Gruber G, Kannicht C, et al. Characterisation of a novel high-purity, double virus inactivated von Willebrand factor and factor VIII concentrate (Wilate). Biologicals 2006;34:281-8.
85. Burnouf T, Radosevich M. Nanofiltration of plasma-derived biopharmaceutical products. Haemophilia 2003;9:24-37.
86. Seltsam A, Müller TH. Update on the use of pathogen-reduced human plasma and platelet concentrates. Br J Haematol 2013;162:442-54.
87. Picker SM. Current methods for the reduction of blood-borne pathogens: a comprehensive literature review. Blood Transfus 2013;11:343-8.
88. Picker SM. Pathogen reduction technologies: the best solution for safer blood? J Blood Disorders Transf 2012;3:5.
89. Pock K, Heger A, Janisch S, et al. Thrombin generation capacity is impaired in methylene-blue treated plasma compared to normal levels in single-donor fresh-frozen plasma, a licensed solvent/detergent-treated plasma (Octaplas) and a development product (Uniplas). Transfus Apher Sci 2007;37:223-31.
90. Prince AM, Horowitz B, Brotman B. Sterilisation of hepatitis and HTLV-III viruses by exposure to tri (n-butyl) phosphate and sodium cholate. Lancet 1986;1:706-10.
91. Liumbruno GM, Franchini M. Solvent/detergent plasma: pharmaceutical characteristics and clinical experience. J Thromb Thrombolysis 2015;39:118-28.
92. Hambleton J, Wages D, Radu-Radulescu L, et al. Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin. Transfusion 2002;42:1302-7.
93. Ciaravino V, Hanover J, Lin L, et al. Assessment of safety in neonates for transfusion of platelets and plasma prepared with amotosalen photochemical pathogen inactivation treatment by a 1-month intravenous toxicity study in neonatal rats. Transfusion 2009;49:985-94.
94. Seifried E, Henschler R, Müller MM. European perspectives on implementation. In: AuBuchon JP, Prowse C, editors: Pathogen Inactivation: The Penultimate Paradigm Shift. Bethesda: AABB Press; 2010. p. 261-78.
95. Pamphilon D. Viral inactivation of fresh frozen plasma. Br J Haematol 2000;109:680-93.
96. Solheim BG, Svennevig JL, Mohr B, et al. The use of Octaplas in patients undergoing open heart surgery. In: Müller-Berghaus G, editor. DIC: Pathogenesis, Diagnosis and Therapy of Disseminated Intravascular Fibrin Formation. Amsterdam: Elsevier; 1993. p. 253-62.
97. FDA Blood Products Advisory Committee 104th Meeting, September 20, 2012. Issue Summary - Topic II: Safety and efficacy of Octaplas LG, solvent/detergent, ligand gel affinity chromatography treated plasma. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/BloodProductsAdvisoryCommittee/UCM319773.pdf. Accessed on 02/12/2014.
98. Department of Health measures currently in place in the UK to reduce the potential risk of vCJD transmission via blood. April 2013. Available at: https://www.gov. uk/government/news/measures-currently-in-place-in-the-uk-to-reduce-thepotentialrisk-of-vcjd-transmission-via-blood. Accessed on 02/12/2014.
99. Lozano M, Cid J, Müller TH. Plasma treated with methylene blue and light: clinical efficacy and safety profile. Transfus Med Rev 2013;27:235-40.
100. ® pathogen reduction technology system. Transfus Med Hemother 2013;40:44-8.
101. Meddeviceonline. CaridianBCT Receives CE Mark For Mirasol Pathogen Reduction Technology System For Plasma. Available at: http://www.meddeviceonline.com/doc/caridianbct-receives-ce-mark-for-mirasol-0001. Accessed on 02/12/2014.
102. Edwin Poots, MLA Tours Terumo BCT Northern Ireland, Manufacturing Facility. 2015 TERUMO BCT. Available at: https://www.terumobct.com/location/japan/about-terumobct/press-room/Pages/21-AUG,-2014-Edwin-Poots,-MLATours-Terumo-BCT-Northern-Ireland,-Manufacturing-Facility.aspx. Accessed on 02/12/2014.
103. Marschner S, Goodrich R. Pathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV light. Transfus Med Hemother 2011;38:8-18.
104. Dichtelmüller HO, Biesert L, Fabbrizzi F, et al. Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies. Transfusion 2009;49:1931-43.
105. Burnouf T, Goubran HA, Radosevich M, et al. Impact of Triton X-100 on alpha 2-antiplasmin (SERPINF2) activity in solvent/detergent-treated plasma. Biologicals 2007;35:349-53.
106. Horowitz B: United States: solvent/detergent plasma. In: AuBuchon JP, Prowse CV, editors. Pathogen Inactivation: The Penultimate Paradigm Shift. Bethesda: AABB Press; 2010. p. 217-28.
107. Roberts P, Sims G. Use of vegetable-derived Tween 80 for virus inactivation by solvent/detergent treatment. Biologicals 1999;27:263-4.
108. Klein HG, Dodd RY, Dzik WH, et al. Current status of solvent/detergent-treated frozen plasma. Transfusion 1998;38:102-7.
109. Piquet Y, Janvier G, Selosse P, et al. Virus inactivation of fresh frozen plasma by a solvent detergent procedure: biological results. Vox Sang 1992;63:251-6.
110. Andreu G: France: solvent/detergent plasma. In: AuBuchon JP, Prowse CV, editors. Pathogen Inactivation: The Penultimate Paradigm Shift. Bethesda: AABB Press; 2010. p. 137-51.
111. Hellstern P, Sachse H, Schwinn H, Oberfrank K. Manufacture and in-vitro characterization of solvent/detergent-treated plasma. Vox Sang 1992;63:178-85.
112. Biesert L, Suhartono H. Solvent/detergent treatment of human plasma - a very robust method for virus inactivation. Validated virus safety of OCTAPLAS. Vox Sang 1998;74:207-12.
113. Heger A, Svae T-E, Neisser-Svae A, et al. Biochemical quality of the pharmaceutical licensed plasma OctaplasLG after implementation of a novel prion protein (PrPSc) removal technology and reduction of the solvent/detergent (SD) process time. Vox Sang 2009;97:219-25.
114. Ekiaby M, Sayed MA, Caron C, et al. Solvent-detergent filtered (SD-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system. Transfus Med 2010;20:48-61.
115. El-Burnouf T, Goubran HA, Radosevich M, et al. A process for solvent/detergent treatment of plasma for transfusion at blood centres that use a disposable bag system. Transfusion 2006;46:2100-8.
116. El-Ekiaby M, Radosevich M, Goubran H, et al. New methods of plasma fractionation - a presentation of the 'mini-pool' fractionation procedure developed in Egypt. ISBT Science Series 2009;4:99-106.
117. Horowitz B, Prince AM, Hamman J, Watklevicz C. Viral safety of solvent/detergent-treated blood products. Blood Coagul Fibrinolysis 1994;5:S21-8; discussion S29-30.
118. Solheim BG, Rollag H, Svennevig JL, et al. Viral safety of solvent/detergent-treated plasma. Transfusion 2000;40:84-90.
119. Pelletier JP, Transue S, Snyder EL. Pathogen inactivation techniques. Best Pract Res Clin Haematol 2006;19:205-42.
120. ® manufacturing-results from animal bioassay studies. Vox Sang 2012;102:294-301.
121. Svae TE, Neisser-Svae A, Bailey A, et al. Prion safety of transfusion plasma and plasma-derivatives typically used for prophylactic treatment. Transfus Apher Sci 2008;39:59-67.
122. Agner SJ. Virus inactivation in blood components by photoactive phenothiazine dyes. Transfus Med Rev 2002;16:61-6.
123. Seghatchian J, Krailadsiri P. What's happening? The quality of methylene blue treated FFP and cryo. Transfus Apher Sci 2001;25:227-31.
124. Seghatchian J, Walker WH, Reichenberg S. Updates on pathogen inactivation of plasma using Theraflex methylene blue system. Transfus Apher Sci 2008;38:271-80.
125. Lozano M, Cid J. Pathogen inactivation: coming of age. Curr Opin Hematol 2013;20:540-5.
126. Mohr H, Lambrecht B, Seltz A. Photodynamic virus inactivation of blood components. Immunol Invest 1995;24:73-85.
127. Williamson LM, Cardigan R, Prowse CV. Methylene bluetreated fresh-frozen plasma: what is its contribution to blood safety? Transfusion 2003;43:1322-9.
128. Mohr H. Methylene blue and thionine in pathogen inactivation of plasma and platelet concentrates. Transfus Apher Sci 2001;25:183-4.
129. Wainwright M, Mohr H, Walker WH. Phenothiazinium derivatives for pathogen inactivation in blood products. J Photochem Photobiol B 2007;86:45-58.
130. Abe H, Yamada-Ohnishi Y, Hirayama J, et al. Elimination of both cell-free and cell-associated HIV infectivity in plasma by a filtration/methylene blue photoinactivation system. Transfusion 2000;40:1081-7.
131. Knuver-Hopf J, Mohr H. Parvovirus B19 is sensitive to photodynamic and photochemical treatment. Abstract Book VIII European Congress of the ISBT; 2003;94.
132. Knuver-Hopf J, Schaefer W, Groener A, et al. Human parvovirus in plasma is highly sensitive to methylene blue/light treatment. Vox Sang 2010;99:1-516.
133. Gironés N, Bueno JL, Carrión J, et al. The efficacy of photochemical treatment with methylene blue and light for the reduction of Trypanosoma cruzi in infected plasma. Vox Sang 2006;91:285-91.
134. Achour A. Phenothiazines and prion diseases: a potential mechanism of action towards oxidative stress. Int J Antimicrob Agents 2002;20:305-6.
135. Amaral L, Kristiansen JE. Phenothiazines: potential management of Creutzfeldt-Jacob disease and its variants. Int J Antimicrob Agents 2001;18:411-7.
136. Wagstaff DJ. Dietary exposure to furocoumarins. Regul Toxicol Pharmacol 1991;14:261-72.
137. Lin L, Cook DN, Wiesehahn GP, et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 1997;37:423-35.
138. Cid J, Ramiro L, Martínez N, et al. Quantitative and qualitative analysis of proteins in fresh frozen plasma obtained from whole blood donations and prepared with two photochemical treatments. Transfus Apher Sci 2008;39:115-21.
139. Cazenave JP. Photochemical inactivation of pathogens in platelets and plasma: five years of clinical use in routine and hemovigilance. Towards a change of paradigm in transfusion safety. Transfus Clin Biol 2011;18:53-61.
140. Roback JD, Conlan M, Drew WL, et al. The role of photochemical treatment with amotosalen and UV-A light in the prevention of transfusion-transmitted cytomegalovirus infections. Transfus Med Rev 2006;20:45-56.
141. Lin L, Hanson CV, Alter HJ, et al. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 2005;45:580-90.
142. Cid J, Escolar G, Lozano M. Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta-analysis of randomized controlled trials. Vox Sang 2012;103:322-30.
143. Grellier P, Benach J, Labaied M, et al. Photochemical inactivation with amotosalen and long-wavelength ultraviolet light of Plasmodium and Babesia in platelet and plasma components. Transfusion 2008;48:1676-84.
144. Goodrich RP, Edrich RA, Li J, Seghatchian J. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 2006;35:5-17.
145. ® pathogen reduction technology system and quality of platelets stored in platelet additive solution. Blood Transfus 2010;8:186-92.
146. Douki T, Laporte G, Cadet J. Inter-strand photoproducts are produced in high yield within A-DNA exposed to UVC radiation. Nucleic Acids Res 2003;31:3134-42.
147. Kumar V, Lockerbie O, Keil SD, et al. Riboflavin and UVlight based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem Photobiol 2004;80:15-21.
148. Silliman CC, Khan SY, Ball JB, et al. Mirasol pathogen reduction technology treatment does not affect acute lung injury in a two-event in vivo model caused by stored blood components. Vox Sang 2010;98:525-30.
149. Allain JP, Bianco C, Blajchman MA, et al. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. Transfus Med Rev 2005;19:110-26.
150. Kiang Tan L, Lam S, Low S, et al. Evaluation of pathogen reduction systems to inactivate Dengue and Chikungunya viruses in apheresis platelets suspended in plasma. Advances in Infectious Diseases 2013;3:1-9.
151. Burnouf T, Chou ML, Cheng LH, et al. Dengue virus inactivation by minipool TnBP/Triton X-45 treatment of plasma and cryoprecipitate. Vox Sang 2013;104:1-6.
152. ®) and in the universally applicable plasma (Uniplas) in development. Vox Sang 2007;92:206-12.
153. ®) does not induce complement-mediated hemolysis of human red blood cells in vitro. Transfus Apher Sci 2015;52:128-35.
154. Macopharma. Blood Safety Website. Available at: http://www.macopharma.com/en/theraflex-methylene-blue-MB plasma. Accessed on 02/12/2014.
155. Steinmann E, Gravemann U, Friesland M, et al. Two pathogen reduction technologies-methylene blue plus light and shortwave ultraviolet light-effectively inactivate hepatitis C virus in blood products. Transfusion 2013;53:1010-8.
156. INTERCEPT eNews delivers product news & information updates. Available at: http://www.interceptbloodsystem. com/product-overview/intercept-plasma. Accessed on 02/12/2014.
157. de Cock P et al. The Mirasol Evaluation Program: use of Mirasol pathogen reduction technology for platelets in routine clinical practice. Transfusion 2008;48:156A.
158. Custer B. Update on pathogen reduction technology. ISBT Science Series 2013;8:80-84
159. ® pathogen reduction technology (PRT) system. A simple, proven system with built-in flexibility. Available at: https://www.terumobct.com/location/asia-pacific/Documents/306690275A-MiraSimplicity-web.pdf Accessed on 02/12/2014.
160. Evans G, Llewelyn C, Luddington R, et al. Solvent/detergent fresh frozen plasma as primary treatment of acute thrombotic thrombocytopenic purpura. Clin Lab Haematol 1999;21:119-23.
161. Williamson LM, Llewelyn CA, Fisher NC, et al. A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation. Transfusion. 1999;39:1227-34.
162. Flamholz R, Jeon HR, Baron JM, Baron BW. Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent/detergent-treated plasma: is its decreased protein S activity clinically related to their development of deep venous thromboses? J Clin Apher 2000;15:169-72.
163. Lerner RG, Nelson J, Sorcia E, et al. Evaluation of solvent/detergent-treated plasma in patients with a prolonged prothrombin time. Vox Sang 2000;79:161-7.
164. Atance R, Pereira A, Ramírez B. Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. Transfusion 2001;41:1548-52.
165. de la Rubia J, Arriaga F, Linares D, et al. Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura. Br J Haematol 2001;114:721-3.
166. Haubelt H, Blome M, Kiessling AH, et al. Effects of solvent/detergent-treated plasma and fresh-frozen plasma on haemostasis and fibrinolysis in complex coagulopathy following open-heart surgery. Vox Sang 2002;82:9-14.
167. Noddeland H, Töllöfsrud S, Svennevig J, et al. Universal solvent/detergent-treated fresh frozen plasma (Uniplas-rationale and clinical properties. Thromb Res 2002;107:S33-7.
168. de Jonge J, Groenland TH, Metselaar HJ, et al. Fibrinolysis during liver transplantation is enhanced by using solvent/detergent virus-inactivated plasma (ESDEP). Anesth Analg 2002;94:1127-31.
169. Alvarez-Larrán A, Del Río J, Ramírez C, et al. Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Vox Sang 2004;86:246-51.
170. de Alarcon P, Benjamin R, Dugdale M, et al. Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies. Transfusion 2005;45:1362-72.
171. García-Noblejas A, Osorio S, Durán AI, et al. Pulmonary embolism in a patient with severe congenital deficiency for factor V during treatment with fresh frozen plasma. Haemophilia 2005;11:276-9.
172. Mintz PD, Neff A, MacKenzie M, et al. A randomized, controlled phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion 2006;46:1693-704.
173. Santagostino E, Mancuso ME, Morfini M, et al. Solvent/detergent plasma for prevention of bleeding in recessively inherited coagulation disorders: dosing, pharmacokinetics and clinical efficacy. Haematologica 2006;91:634-9.
174. Scully M, Longair I, Flynn M, et al. Cryosupernatant and solvent detergent fresh-frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic purpura. Vox Sang 2007;93:154-8.
175. Mikkola R, Gunn J, Heikkinen J, et al. Use of blood products and risk of stroke after coronary artery bypass surgery. Blood Transfus 2012;10:490-501.
176. Mikkola R, Heikkinen J, Lahtinen J, et al. Does blood transfusion affect intermediate survival after coronary artery bypass surgery? Scand J Surg 2013;102:110-6.
177. Stanojkovic Z, Balint B, Antic A, et al. Clinical efficacy of riboflavin and ultraviolet light inactivated fresh frozen plasma evaluated with INR-quantification. Transfus Apher Sci 2012;47:33-7.
178. Bindi ML, Miccoli M, Marietta M, et al. Solvent detergent vs. fresh frozen plasma in cirrhotic patients undergoing liver transplant surgery: a prospective randomized control study. Vox Sang 2013;105:137-43.
179. Bartelmaos T, Chabanel A, Léger J, et al. Plasma transfusion in liver transplantation: a randomized, double-blind, multicenter clinical comparison of three virally secured plasmas. Transfusion 2013;53:1335-45.
180. Beeck H, Hellstern P. In vitro characterization of solvent/detergent-treated human plasma and of quarantine fresh frozen plasma. Vox Sang 1998;74:S219-23.
181. Aznar JA, Molina R, Montoro JM. Factor VIII/von Willebrand factor complex in methylene blue-treated fresh plasma. Transfusion 1999;39:748-50.
182. Doyle S, O'Brien P, Murphy K, et al. Coagulation factor content of solvent/detergent plasma compared with fresh frozen plasma. Blood Coagul Fibrinolysis 2003;14:283-7.
183. Depasse F, Sensebé L, Seghatchian J, et al. The influence of methylene blue light treatment and methylene blue removal filter on fibrinogen activity states and fibrin polymerisation indices. Transfus Apher Sci 2005;33:63-9.
184. Heger A, Römisch J, Svae TE. Stability of solvent/detergenttreated plasma and single-donor fresh-frozen plasma during 48 h after thawing. Transfus Apher Sci 2005;33:57-67.
185. Singh Y, Sawyer LS, Pinkoski LS, et al. Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion 2006;46:1168-77.
186. del Río-Garma J, Pereira A, Arroyo JL, et al; Spanish Group of Apheresis (Grupo Español de AféresisGEA). ADAMTS-13 activity and von Willebrand factor levels in methylene-blue photo-inactivated plasma processed by either the Springe method or an 'in house' system. Vox Sang 2008;95:101-5.
187. Lawrie AS, Green L, Canciani MT, et al. The effect of prion reduction in solvent/detergent-treated plasma on haemostatic variables. Vox Sang 2010;99:232-8.
188. Theusinger OM, Baulig W, Seifert B, et al. Relative concentrations of haemostatic factors and cytokines in solvent/detergent-treated and fresh-frozen plasma. Br J Anaesth 2011;106:505-11.
189. Ettinger A, Miklauz MM, Hendrix BK, et al. Quality of proteins in riboflavin and UV light-treated FFP during 1 year of storage at -18°C. Transfus Apher Sci 2012;46:15-8.
190. Ettinger A, Miklauz MM, Bihm DJ, et al. Preparation of cryoprecipitate from riboflavin and UV light-treated plasma. Transfus Apher Sci 2012;46:153-8.
191. ® LG during storage at 2-6°C for 6 days from a quality assurance point of view. Transfus Apher Sci 2012;46:129-36.
192. Cid J, Caballo C, Pino M, et al. Quantitative and qualitative analysis of coagulation factors in cryoprecipitate prepared from fresh-frozen plasma inactivated with amotosalen and ultraviolet A light. Transfusion 2013;53:600-5.
193. Rock G, Clark WF, Anderson D, et al; Members of the Canadian Apheresis Group. ADAMTS-13 may not predict disease or outcome in patients with thrombotic thrombocytopenic purpura. Thromb Res 2013;131:308-12.
194. Jilma-Stohlawetz P, Kursten FW, Walasek C, et al. Safety of a universal, virus-inactivated and prion-depleted, pharmaceutical-quality plasma: a randomized, double-blind, clinical trial in healthy volunteers. Transfusion 2011;51:1228-40.
195. Jilma-Stohlawetz P, Kursten FW, et al. Recovery, safety, and tolerability of a solvent/detergent-treated and prionsafeguarded transfusion plasma in a randomized, crossover, clinical trial in healthy volunteers. Transfusion 2013;53:1906-17.
196. Bolton-Maggs PH, Cohen H. Serious Hazards of Transfusion (SHOT) haemovigilance and progress is improving transfusion safety. Br J Haematol 2013;163:303-14.
197. Stramer SL, Hollinger FB, Katz LM, et al. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009;49:1S-29S.
198. MacLennan S, Barbara JA. Risks and side effects of therapy with plasma and plasma fractions. Best Pract Res Clin Haematol 2006;19:169-89.
199. Funk MB, Guenay S, Lohmann A, et al. Benefit of transfusion-related acute lung injury risk-minimization measures-German haemovigilance data (2006-2010). Vox Sang 2012;102:317-23.
200. Pandey S, Vyas GN. Adverse effects of plasma transfusion. Transfusion 2012;52:65S-79S.
201. Evidence-Based Medicine Group. San Giovanni Battista Hospital, Turin, Italy. [The transfusion of plasma in adults.] November 2006. Available at: http://old.cpo.it/lineeguida/lgplasma.pdf. Accessed on 10/12/2014. [In Italian.]
202. McCullough J. Pathogen inactivation: a new paradigm for preventing transfusion-transmitted infections. Am J Clin Pathol 2007;128:945-55.
203. Neisser-Svae A, Bailey A, Gregori L, et al. Prion removal effect of a specific affinity ligand introduced into the manufacturing process of the pharmaceutical quality solvent/detergent (SD) - treated plasma OctaplasLG. Vox Sang 2009;97:226-33.
204. Bolton-Maggs PH, Poles D, Watt A, Thomas D; on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2013 Annual SHOT Report (2014).
205. Canadian Agency for Drugs and Technologies in Health, CADHT Technology report, 2007. A systematic review of clinical, laboratory and safety outcomes associated with use of Octaplas in multiple clinical indications.
206. Canadian Agency for Drugs and Technologies in Health, CADHT Technology report, 2010. Update. A systematic review of clinical, laboratory and safety outcomes associated with use of Octaplas in multiple clinical indications.
207. Flesland O. A comparison of complication rates based on published haemovigilance data. Intensive Care Med 2007;33:S17-21.
208. Cazenave JP, Waller C, Kientz D, et al. An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment. Transfusion 2010;50:1210-9.
209. Canadian Agency for Drugs and Technologies in Health, CADHT Systematic Review, 2010. Pathogen Reduction Technologies for Blood Products: A Review of the Clinical Effectiveness, Cost-Effectiveness, and Guidelines.
210. European Commission, Health and Consumers Directorate-General, 2013. Summary of the 2013 annual reporting of serious adverse events and reactions (SARE) for blood and blood components. Available at: http://ec.europa.eu/health/blood-tissues-organs/docs/blood-sare-2013-en. pdf. Accessed on 01/12/2014.
211. The Paul-Ehrlich-Institut. Assessment of the Reports of Serious Adverse Transfusion Reactions pursuant to Section 63 c AMG (Arzneimittelgesetz, German Medicinal Products Act), 2010. Available at: http://www.pei.de/SharedDocs/Downloads/vigilanz/haemovigilanz/publikationen/haemovigilancereport-2010.pdf?-blob=publicat ionFile&v=5. Accessed on 01/12/2014.
212. Knowles S, Cohen H; on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2010 Annual SHOT Report (2011). Available at: http://www.shotuk.org/shot-reports/. Accessed on 01/12/2014.
213. Bolton-Maggs PH, Cohen H; on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2011 Annual SHOT Report (2012). Available at: http://www.shotuk.org/shot-reports/. Accessed on 01/12/2014.
214. Bolton-Maggs PH, Poles D, Watt A; on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2012 Annual SHOT Report (2013). Available at: http://www.shotuk.org/shot-reports/. Accessed on 01/12/2014.
215. Irish National Haemovigilance Office. NHO REPORT 2008/2009. Available at: http://www.giveblood.ie/Clinical-Services/Haemovigilance/Publications/. Accessed on 01/12/2014.
216. Irish National Haemovigilance Office. NHO REPORT 2010/2011. Available at: http://www.giveblood.ie/Clinical-Services/Haemovigilance/Publications/. Accessed on 01/12/2014.
217. Swissmedical. Haemovigilance Annual report 2010. Available at: https://www.swissmedic.ch/marktueberwachung/00138/00188/index.html?lang=en. Accessed on 02/12/2014.
218. Swissmedical. Haemovigilance Annual report 2011. Available at: https://www.swissmedic.ch/marktueberwachung/00138/00188/index.html?lang=en. Accessed on 02/12/2014.
219. Swissmedical. Haemovigilance Annual report 2012. Available at: https://www.swissmedic.ch/marktueberwachung/00138/00188/index.html?lang=en. Accessed on 02/12/2014.
220. Swissmedical. Haemovigilance Annual report 2013. Available at: https://www.swissmedic.ch/marktueberwachung/00138/00188/index.html?lang=en. Accessed on 02/12/2014.
221. Agence Française de Sécurité Sanitaire des produits de Santé (AFSSAPS). Haemovigilance Annual report 2008. Available at: http://ansm.sante.fr/Mediatheque/Publications/Information-in-English. Accessed on 02/12/2014.
222. Agence Française de Sécurité Sanitaire des produits de Santé (AFSSAPS). Haemovigilance Annual report 2009. Available at: http://ansm.sante.fr/Mediatheque/Publications/Information-in-English. Accessed on 02/12/2014.
223. Politis C, Kavallierou L, Hantziara S, et al. Haemovigilance data on the use of methylene blue virally inactivated fresh frozen plasma with the Theraflex MB plasma System in comparison to quarantine plasma: 11 years' experience. Transfus Med 2014;24:316-20.
224. Muñiz-Diaz E, Puig L. Allergic and anaphylactic reactions to methylene-blue-treated plasma in Catalonia in the period 2008-2013. Blood Transfus 2014;12:628-30.
225. Bost V, Odent-Malaure H, Chavarin P, et al. A regional haemovigilance retrospective study of four types of therapeutic plasma in a ten-year survey period in France. Vox Sang 2013;104:337-41.
226. Nubret K, Delhoume M, Orsel I, et al. Anaphylactic shock to fresh-frozen plasma inactivated with methylene blue. Transfusion 2011;51:125-8.
227. Norda R, Tynell E, Akerblom O. Cumulative risks of early fresh frozen plasma, cryoprecipitate and platelet transfusion in Europe. J Trauma 2006;60:S41-5.
228. Dewachter P, Castro S, Nicaise-Roland P, et al. Anaphylactic reaction after methylene blue-treated plasma transfusion. Br J Anaesth 2011;106:687-9.
229. Eder AF, Herron RM Jr, Strupp A, et al. Effective reduction of transfusion-related acute lung injury risk with malepredominant plasma strategy in the American Red Cross (2006-2008). Transfusion 2010;50:1732-42.
230. Hauser L, Roque-Afonso AM, Beylouné A, et al. Hepatitis E transmission by transfusion of Intercept blood system-treated plasma. Blood 2014;123:796-7.
231. International Haemovigilance Network. Proposed Standard Definitions For Surveillance Of Non Infectious Adverse Transfusion Reactions; 2011. Available at: http://www.ihn-org. com/wp-content/uploads/2011/06/ISBT-definitions-for-noninfectioustransfusion-reactions.pdf. Accessed on 01/12/2014.
232. Solheim BG. Pathogen reduction of blood components. Transfus Apher Sci 2008;39:75-82.
233. ® version 2.0; 2013. Available at: http://www.corehta. info/BrowseModel.aspx. Accessed on 10/12/2014.
234. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.
235. Riedler GF, Haycox AR, Duggan AK, Dakin HA. Costeffectiveness of solvent/detergent-treated fresh frozen plasma. Vox Sang 2003;85:88-95.
236. ®) versus fresh frozen plasma (FFP) in critically ill patients in the UK. Transfus Apher Sci 2010;3:251-9.
237. Blumberg N, Heal JM. Mortality risks, costs, and decision making in transfusion medicine. Am J Clin Pathol 2000;114:934-7.
238. Huisman EL, de Silva SU, de Peuter MA. Economic evaluation of pooled solvent/detergent treated plasma versus single donor fresh-frozen plasma in patients receiving plasma transfusions in the United States. Transfus Apher Sci 2014;51:17-24.
239. AuBuchon JP, Birkmeyer JD. Safety and cost-effectiveness of solvent-detergent-treated plasma. In search of a zero-risk blood supply. JAMA 1994;272:1210-4.
240. Pereira A. Cost-effectiveness of transfusing virus-inactivated plasma instead of standard plasma. Transfusion 1999;39:479-87.
241. ®) versus freshfrozen plasma (FFP) in any patient receiving transfusion in Canada. Transfus Apher Sci 2014;51:25-34.
242. Taylor C, Cohen H, Mold D, Jones H; on behalf of the Serious Hazards of Transfusion (SHOT) steering group. The 2008 Annual SHOT Report; 2009. Available at: http://www.shotuk.org/shot-reports/report-and-summary-2009/. Accessed on 01/12/2014.
243. Ofosu FA, Freedman J, Semple JW. Plasma-derived biological medicines used to promote haemostasis. Thromb Haemost 2008;99:851-62.
244. Liumbruno GM, Panetta V, Bonini R, et al. Institutional authorization and accreditation of Transfusion Services and Blood Donation Sites: results of a national survey. Blood Transfus 2011;9:436-54.
245. Hellstern P. Solvent/detergent-treated plasma: composition, efficacy, and safety. Curr Opin Hematol 2004;11:346-50.
246. Sharma AD, Sreeram G, Erb T, Grocott HP. Solventdetergenttreated fresh frozen plasma: a superior alternative to standard fresh frozen plasma? J Cardiothorac Vasc Anesth 2000;14:712-7.
247. Koenigbauer UF, Eastlund T, Day JW. Clinical illness due to parvovirus B19 infection after infusion of solvent/detergenttreated pooled plasma. Transfusion 2000;40:1203-6.
248. Ruggeri M, Marietta M, Krusius T. Plasma S/D: le ragioni di una scelta. J Health Sci 2014;17.
249. Vamvakas EC, Blajchman MA. Blood still kills: six strategies to further reduce allogeneic blood transfusion-related mortality. Transfus Med Rev 2010;24:77-124.
250. Klein HG, Glynn SA, Ness PM, et al. Research opportunities for pathogen reduction/inactivation of blood components: summary of an NHLBI workshop. Transfusion 2009;49:1262-8.
251. Alter HJ. Pathogen reduction: a precautionary principle paradigm. Transf Med Rev 2008;22:97-102.
252. Official Journal of Italian Republic n. 80, 7 April 2015. Decreto Ministeriale 5 dicembre 2014. "Individuazione dei centri e aziende di frazionamento e di produzione di emoderivati autorizzati alla stipula delle convenzioni con le regioni e le province autonome per la lavorazione del plasma raccolto sul territorio nazionale".
253. Official Journal of the European Union n. L 311, 28 November 2001. Directive 2001/83/CE on the Community code relating to medicinal products for human use.
254. Official Journal of the European Union n. L 33, 8 February 2003. Directive 2002/98/EC of the European Parliament and of the Council of 27 January 2003 setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components and amending Directive 2001/83/EC
255. Official Journal of the European Union n. L 262, 14 October 2003. Commission Directive 2003/94/EC of 8 October 2003 "laying down the principles and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal products for human use".
256. World Health Organization. Safe Blood and Blood Products: Manual on the Management, Maintenance and Use of Blood Cold Chain Equipment. Geneva: WHO; 2005. Available at: http://www.who.int/bloodsafety/Manual-on-Management, Maintenance-and-Use-of-Blood-Cold-Chain-Equipment.pdf. Accessed on 01/12/2014.
257. Di Fazio C. Studio sulla validazione del congelamento del plasma. Undergraduate dissertation. Biomedical engineering, Engineering school. Università degli studi di Padova. 2012.
258. Official Journal of Italian Republic n. 233, 6 October 2005. Decreto Legislativo 19 agosto 2005 n. 191. "Attuazione della direttiva 2002/98/CE che stabilisce norme di qualità e di sicurezza per la raccolta, il controllo, la lavorazione, la conservazione e la distribuzione del sangue umano e dei suoi componenti".
259. Official Journal of Italian Republic n. 19, 23 January 2008. Decreto Legislativo 20 dicembre 2007, n. 261. "Revisione del decreto legislativo 19 agosto 2005, n. 191, recante attuazione della direttiva 2002/98/CE che stabilisce norme di qualità e di sicurezza per la raccolta, il controllo, la lavorazione, la conservazione e la distribuzione del sangue umano e dei suoi componenti".
260. Official Journal of Italian Republic n. 261, 9 November 2007. Decreto Legislativo 9 novembre 2007, n. 207. "Attuazione della direttiva 2005/61/CE che applica la direttiva 2002/98/CE per quanto riguarda la prescrizione in tema di rintracciabilità del sangue e degli emocomponenti destinati a trasfusioni e la notifica di effetti indesiderati ed incidenti gravi".
261. Official Journal of Italian Republic n. 261, 9 November 2007. Decreto Legislativo 9 novembre 2007, n. 208. "Attuazione della direttiva 2005/62/CE che applica la direttiva 2002/98/CE per quanto riguarda le norme e le specifiche comunitarie relative ad un sistema di qualità per i servizi trasfusionali".
262. Official Journal of the European Union n. L 256, 1 ottobre 2005. Commission Directive 2005/62/CE of 30 September 2005 implementing Directive 2002/98/EC of the European Parliament and of the Council as regards Community standards and specifications relating to a quality system for blood establishments.
263. Official Journal of the European Union n. L 91, 30 March 2004. Commission Directive 2004/33/CE of 22 March 2004 implementing Directive 2002/98/EC of the European Parliament and of the Council as regards certain technical requirements for blood and blood components.
264. Official Journal of the European Union n. L 256, 1 October 2005. Commission Directive 2005/61/EC of 30 September 2005 implementing Directive 2002/98/EC of the European Parliament and of the Council as regards traceability requirements and notification of serious adverse reactions and events.
265. Official Journal of Italian Republic n. 251, 27 October 2005. Legge 21 Ottobre 2005, n. 219. "Nuova disciplina delle attività trasfusionali e della produzione nazionale degli emoderivati"
266. Official Journal of Italian Republic n. 113, 17 May 2011. Conferenza permanente per i rapporti tra lo Stato, le Regioni e le Province Autonome di Trento e Bolzano. Accordo 16 dicembre 2010. Accordo, ai sensi dell'articolo 4 del decreto legislativo 28 agosto 1997, n. 281, tra il Governo, le Regioni e le Province autonome di Trento e Bolzano sui requisiti minimi organizzativi, strutturali e tecnologici delle attività sanitarie dei servizi trasfusionali e delle unita' di raccolta e sul modello per le visite di verifica. (Rep. Atti n. 242/CSR del 16 dicembre 2010).
267. Official Journal of Italian Republic n. 85, 13 April 2005. Decreto del Ministro della Salute 3 marzo 2005: Protocolli per l'accertamento della idoneità del donatore di sangue e di emocomponenti.
268. Ordinanza 29 marzo 2004 Ministero della Salute. Non idoneità alla donazione di sangue di coloro che hanno soggiornato nel Regno Unito. Gazzetta Ufficiale della Repubblica Italiana, n. 102, 3 maggio 2004.
269. Centro Nazionale Sangue, Agenzia Italiana del Farmaco e Istituto Superiore di Sanità. Gestione delle segnalazioni di donatori con malattia di Creutzfeldt-Jakob (post donation information). Position paper 2012.
270. CHMP Position statement on Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products. European Medicines Agency (EMA); London: Jun. 23, 2011. EMA/CHMP/BWP/303353/2010.
271. Official Journal of the European Union n. L 169, 12 July 1993. Directive 93/42/CEE of the Council of 14 June 1993, concerning medical devices.
272. Official Journal of the European Union n. L 139 del 23 May 1989. Directive 89/336/CEE of the Council of 3 May 1989 on the approximation of the laws of the Member States relating to electromagnetic compatibility.
273. Official Journal of the European Union n. L 077, 26 March 1973. Directive 73/23/CEE of the Council of 19 February 1973 on the harmonisation of the laws of Member States relating to electrical equipment designed for use within certain voltage limits.
274. Official Journal of the European Union n. L 331, 07 December 1998. Directive 98/37/EC of the European Parliament and of the Council of 22 June 1998 on the approximation of the laws of the Member States relating to machinery.
275. European HAS (Harmonised standards): EN 61326:1997. Electrical equipment for measurement, control and laboratory use - EMC requirements - Part 1: General requirements.
276. International standards: EN 61010-1:2001 (General requirements) Safety requirements for electrical equipment for measurement, control, and laboratory use - Part 1: General requirements.
277. European Commission Health and Consumer Protection Directorate General Public Health and Risk Assessment Directorate. European Blood Inspection System. Common European Standards and Criteria for the Inspection of Blood Establishments Reflecting European good practice within the area addressing the quality and safety of blood. 2003-2008.
278. Official Journal of the European Union L 102, 7 April 2004. Directive 2004/23/EC of the European Parliament and of the Council of 31 March 2004 on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells.
279. Official Journal of the European Union n. L 159, 26 June 2003. Commission Directive 2003/63/EC of 25 June 2003 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use.
280. Sheffield WP, Bhakta V, Talbot K, et al. Quality of frozen transfusable plasma prepared from whole blood donations in Canada: an update. Transfus Apher Sci 2013;49:440-6.
281. AuBuchon JP, Birkmeyer JD, Busch MP. Safety of the blood supply in the United States: opportunities and controversies. Ann Intern Med 1997;127:904-9.
282. Bacterial contamination of blood components: risks, strategies, and regulation: joint ASH and AABB educational session in transfusion medicine. Hematology/the American Society of Hematology Education Program. 2003.
283. Jorquera JI. Safety procedures of coagulation factors. Hemophilia 2007;13:41-6.
284. Van der Wilt GJ, Reuzel R, Banta HD. The ethics of assessing health technologies. Theor Med Bioeth 2000;21:103-15.
285. Hofmann B. Why ethics should be part of health technology assessment. Int J Technol Assess Health Care 2008;24:423-9.
286. Sacchini D, Virdis A, Refolo P, et al. Health technology assessment (HTA): Ethical aspects. Med Health Care Philos 2009;12:453-7.
287. Assasi N, Schwartz L, Tarride JE, et al. Methodological guidance documents for evaluation of ethical considerations in health technology assessment: a systematic review. Expert Rev Pharmacoecon Outcomes Res 2014;14:203-20.
288. Health Council of the Netherlands. Pathogen reduction in blood products. The Hague: Health Council of the Netherlands, 2003; publication no. 2003/16E.
289. Refolo P, Sacchini D, Minacori R, Spagnolo AG. [Internet use in clinical trials]. Clinica Terapeutica 2014;165:e79-85. [In Italian.]
290. Berto D, Peroni M, Milleri S, Spagnolo AG. Evaluation of the readability of information sheets for healthy volunteers in phase-I trials. Eur J Clin Pharmacol 2000;56:371-4.
291. Refolo P, Minacori R, Mele V, et al. Patient-reported outcomes (PROs): the significance of using humanistic measures in clinical trial and clinical practice. Eur Rev Med Pharmacol Sci 2012;16:1319-23.
292. Minacori R, Sacchini D, Cicerone M, Spagnolo AG. Insurance and clinical trials. Contemp Clin Trials 2012;33:573.
293. Refolo P, Mele V, Minacori R, Spagnolo AG. [Patientreported outcomes (PRO): Historical profile, definitions, classifications and problems.] Clinica Terapeutica 2012;163:39-45. [In Italian.]
294. National Advisory Committee on Bioethics. Department of Health. Specific Informed Consent for Blood Transfusion: The Ethical Considerations; 2013. Avaialble at: http://www.dohc.ie/working-groups/Current/nacb/SpecificConsent-Blood%20Transfusion.pdf?direct=1. Accessed on 10/12/2014.
295. Rodriguez del Pozo P. Paying donors and the ethics of blood supply. Med Ethics 1994;20:31-5.
296. Buyx AM. Blood donation, payment, and non-cash incentives: classical questions drawing renewed interest. Transfus Med Hemother 2009;36:329-39.
297. McQuillen MP. Ethical lessons learned from the use of therapeutic plasma exchange in neurologic disease. Ther Apher 2000;4:190-4.
298. Sazama K. The ethics of blood management. Vox Sang 2007;92:95-102.
299. Sazama K. Managing infectious or untested autologous blood components: the ethical dilemma of private rights versus public safety. Arch Pathol Lab Med 2005;129:1212-3.
300. Farrugia A1, Penrod J, Bult JM. Payment, compensation and replacement - the ethics and motivation of blood and plasma donation. Vox Sang 2010;99:202-11.
301. Weiskopf RB. The ethics of blood management. Vox Sang 2007;93:91.
302. Sacchini D, Liumbruno GM, Bruno G, et al. Ethical and deontological issues in Transfusion Medicine. Blood Transfus 2013;11:14-23.
303. Farrell AM, Brazier M. Patients should consent to blood transfusion. Br Med J 2010;341:c4336.
304. Holland PV. Consent for transfusion: is it informed? Transfus Med Rev 1997;11:274-85.
305. Court EL, Robinson A, Hocken DB. Informed consent and patient understanding of blood transfusion. Transf Med 2011;21:183-9.
306. Official Journal of Italian Republic n. 85, April 13th, 2005. Decreto del Ministro della Salute 3 marzo 2005: "Caratteristiche e modalità per la donazione del sangue e di emocomponenti".
307. Judgment of the Court (First Chamber) 13 March 2014, (Approximation of laws - Directive 2001/83/EC - Directive 2002/98/EC - Scope - Labile blood product - Plasma prepared by means of an industrial process - Simultaneous or exclusive application of the directives - Option for a Member State to provide for a more rigorous regime for plasma than for medicinal products) - (C 512/12).
308. Conseil d'Etat sentence no. 357463 between MacoPharma and the Agence Française de Sécurité des Produits de Santé, France. Available at: https://www.legifrance.gouv. fr/affichJuriAdmin. do?oldAction=rechJuriAdmin&idTexte= CETATEXT000029288214&fastReqId=233964865&fastP os=1. Accessed on 10/12/2014.
309. Official Journal of Italian Republic n. 3, 16 January 2008. Italian Ministerial Decree 21 December 2007. New legislation on transfusions and national production of blood products.
310. Council of Europe, Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine, Oviedo, 4-IV-1997.
311. Additional Protocol to the Convention on Human Rights and Biomedicine, concerning Biomedical Research, Strasbourg, 25. I. 2005
312. World Medical Association. WMA Publishes its Revised Declaration of Helsinki, 2013. Available at: http://www.wma.net/en/40news/20archives/2013/2013-28/. Accessed on 10/12/2014.
313. Official Journal of the European Union n. L 281, 23 November 1995. European Parliament And Council, Directive 95/46/EC of 24 October 1995 on the protection of individuals with regard to the processing of personal data and on the free movement of such data.
314. European Convention For The Protection Of Human Rights And Fundamental Freedoms, Rome 4. XI. 1950.
315. Court Of Justice Of European Union, Judgment 20 May 2003, Joined Case C-465/00, C-138/01, C-139/01.
316. Committee On Bioethics (DH-BIO) Working document on research on biological materials of human origin, DH-BIO/INF (2014) 3, Strasbourg, 18 March 2014.
317. National Advisory Committee on Bioethics - Department of Health. Specific Informed Consent for Blood Transfusion: The Ethical Considerations; January 2013. Available at: http://health.gov. ie/wp-content/uploads/2014/07/SpecificConsent-Blood-Transfusion1.pdf. Accessed on 10/12/2014.
318. Repealed by Decision No 1350/2007/EC of the European Parliament and of the Council of 23 October 2007 establishing a second programme of Community action in the field of health (2008-13). Official Journal L 301 of 20.11. 2007.
319. Commission, White Paper "Together for Health: A Strategic Approach for the EU 2008-2013, COM (2007) 630
320. Commission of the European Communities, Communication from the Commission to the Council, the European Parliament, the European Economic and Social Committee and the Committee of the Regions e-health - making healthcare better for European citizens: an Action plan for a European e-Health area, {SEC (2004) 539}, Brussels, 30.4.2004, COM (2004) 356 final.
321. European Parliament - Council of the European Union. 2011/24/UE Directive of the 9 March 2011 concerning the application of patients' rights in cross-border healthcare.
322. Council of Europe, Committee of Ministers. Recommendation Rec (2006) 18 on health services in a multicultural society (adopted by the Committee of Ministers on 8 November 2006 at the 979th meeting of the Ministers' Deputies).
323. Council of the European Union. Directive on cross-border healthcare, 28/02/2011.
324. Court of Justice of the European Union 28/04/1998 (C-120/95). Judgment of the Court of 28 April 1998. Nicolas Decker v Caisse de maladie des employés privés. Reference for a preliminary ruling: Conseil arbitral des assurances sociales - Grand Duchy of Luxemburg. Free movement of goods - Articles 30 and 36 of the EC Treaty - Reimbursement of medical expenses incurred in another Member State - Prior authorisation of the competent institution - Purchase of spectacles.
325. Official Journal of the European Union L 213, 30 July 1998. Directive 98/44/EC of the European Parliament and of the Council of 6 July 1998 on the legal protection of biotechnological inventions.
326. EUnetHTA, Work Package 4 (2008). The HTA Core Model, HTA Core Model for Medical and Surgical Interventions (v 1.0r). Available at: http://www.eunethta.eu/outputs/hta-core-model-diagnostic-technologies-10r. Accessed on 11/07/2014.
327. Ovretveit J. The contribution of new social science research to patient safety. Soc Sci Med 2009;69:1780-3.
328. Lehoux P, Williams-Jones B. Mapping the integration of social and ethical issues in Health Technology Assessment. Int J Technol Assess Health Care 2007;23:9-16.
329. Whyte SR. Questioning misfortune the pragmatics of uncertainty in Eastern Uganda. Cambridge: Cambridge University Press; 1997.
330. Bech U. Risk society. Towards a new modernity. New Delhi: Sage; 1992.
331. Bourdieu P. Social being, time and the sense of existence. In: Bourdieu P, editor. Pascalian Meditations. New York: Polity Press; 2000. p. 206-45.
332. Good BJ. Medicine, rationality, and experience an anthropological perspective. Cambridge: Cambridge University Press; 1994.
333. Foucault M, Martin LH, Gutman H, Hutton PH. Technologies of the self: a seminar with Michel Foucault. Amherst: University of Massachusetts Press; 1988.
334. Jackson M. Minima ethnographic intersubjectivity and the anthropological project. Chicago: University of Chicago Press; 1998.
335. Latour B. 'Constitution' I: we have never been modern. London: Prentice Hall; 1993.
336. Kleinman A. Introduction: medical Anthropology as intellectual career. In: Kleinman A, editor. Writing at the Margin. Discourse between Anthropology and Medicine. Berkeley/Los Angeles/London: University of California Press; 1995. p. 1-20.
337. Bijker WE, Law J., editors. Shaping technology/building society. Studies in sociotechnical change. Cambridge, MA: MIT Press; 1992.
338. Harbers H. Inside the politics of technology: agency and normativity in the co-production of technology and society. Amsterdam: Amsterdam University Press; 2005.
339. Reid S, Johnson L, Woodland N, Marks DC. Pathogen reduction treatment of buffy coat platelet concentrates in additive solution induces proapoptotic signaling. Transfusion 2012;52:2094-103.
340. Denis J-L, Lehoux P, Champagne F. Knowledge utilization in health care: From fine-tuning dissemination to contexualizing knowledge. In: Lemieux-Charles L, Champagne F, editors. Using knowledge and evidence in health care: multidisciplinary perspectives. Toronto: University of Toronto Press; 2004. p. 18-40.
341. Ross SE, Lavis JN, Rodriguez C, et al. Partnership experiences: Involving decision-makers in the research process. J Health Serv Res Policy 2003;8:26-34.
342. Bastian H. Speaking up for ourselves. The evolution of consumer advocacy in health care. Int J Technol Assess Health Care 1998;14:3-23.
343. Mitton C, Smith N, Peacock S, et al. Public participation in health care priority setting: A scoping review. Health Policy 2009;91:219-28.
344. Gauvin F-P, Abelson J, Giacomni M. Conceptualizing public involvement in the context of health technology assessment agencies. Soc Sci Med 2010;70:1518-26.
345. Lehoux P, Daudelin G, Abelson J. The unbearable lightness of citizens within public deliberation processes. Soc Sci Med 2012;74:1843-50.
346. Lehoux P, Blume SS. Technology assessment and the sociopolitics of health technologies. J Health Polit Policy Law 2000;25:1083-120.
347. Lehoux P, Saint-Arnaud J, Richard L. The use of technology at home. What patient manuals say and sell vs. what patients face and fear. Sociol Health Illn 2004;26:617-44.
348. Lehoux P, Daudelin G, Demers-Payette O, Boivin A. Fostering deliberations about health innovations: what do we want to know from publics? Soc Sci Med 2009;68:2002-9.
349. Mooney G. "Communitarian claims" as an ethical basis for allocating health care resources. Soc Sci Med 1998;47:1171-80.